MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) insider Robert Benjamin Stein sold 19,000 shares of the company's stock in a transaction on Monday, September 12th. The stock was sold at an average price of $3.44, for a total transaction of $65,360.00. Following the completion of the sale, the insider now owns 287,002 shares of the company's stock, valued at $987,286.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Robert Benjamin Stein also recently made the following trade(s):
Get
MiMedx Group alerts:
- On Friday, August 12th, Robert Benjamin Stein sold 8,503 shares of MiMedx Group stock. The stock was sold at an average price of $4.04, for a total transaction of $34,352.12.
- On Thursday, August 4th, Robert Benjamin Stein sold 19,500 shares of MiMedx Group stock. The stock was sold at an average price of $3.62, for a total transaction of $70,590.00.
- On Tuesday, June 28th, Robert Benjamin Stein sold 14,600 shares of MiMedx Group stock. The stock was sold at an average price of $3.47, for a total transaction of $50,662.00.
MiMedx Group Stock Down 0.6 %
MiMedx Group stock opened at $3.44 on Friday. The firm has a market cap of $390.81 million, a price-to-earnings ratio of -13.76 and a beta of 1.75. The company has a debt-to-equity ratio of 586.91, a current ratio of 3.53 and a quick ratio of 3.17. MiMedx Group, Inc. has a fifty-two week low of $3.04 and a fifty-two week high of $8.69. The firm has a fifty day moving average price of $3.67 and a two-hundred day moving average price of $3.97.
MiMedx Group (NASDAQ:MDXG – Get Rating) last released its earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The business had revenue of $66.88 million for the quarter, compared to analysts' expectations of $65.07 million. As a group, analysts forecast that MiMedx Group, Inc. will post -0.29 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of MiMedx Group from $8.50 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 7th. StockNews.com lowered shares of MiMedx Group from a "buy" rating to a "hold" rating in a research report on Friday, September 9th.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $41,000. Russell Investments Group Ltd. acquired a new position in shares of MiMedx Group during the second quarter valued at about $28,000. Spinnaker Investment Group LLC acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $47,000. Tiedemann Advisors LLC acquired a new position in shares of MiMedx Group during the first quarter valued at about $49,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group during the first quarter valued at about $50,000. Institutional investors and hedge funds own 60.86% of the company's stock.
About MiMedx Group
(Get Rating)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Read More
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
